Immediately following surgery I was taking Amiodarone for about 3 months. When considering my options, should long-term therapy become necessary, my cardio said he would prefer to switch me from amiodarone to Multaq. He felt that it would affort most of the benefits of amiodarone without the nasty side effects. Fortunately, I haven't needed either since, but if your cardio is suggesting amiodarone, I would ask him/her about Multaq.
There have been quite a few articles lately about problems with Multaq and some countries restricting its use because of the side effects that are showing up. Here is part of one of the recent ones, but if you search Multaq quite a few recnt articles come up
http://www.theheart.org/article/1283205.do
London, UK - The European Medicines Agency (EMA) recommends restricting the use of the antiarrhythmic medication dronedarone (Multaq, Sanofi-Aventis) [1]. The committee states that because of the increased risk of liver, lung, and cardiovascular adverse events, dronedarone "should only be prescribed after alternative treatment options have been considered." Patients currently taking dronedarone should have their treatment reassessed by their physician at their next scheduled visit, the EMA reports....
Dronedarone is currently approved for the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter, and according to the EMA's Committee for Medicinal Products for Human Use (CHMP), the drug should be used only in this population for the maintenance of sinus rhythm.
The recommendations are based on a review of the PALLAS trial, as well as other data suggesting an increased risk of liver and lung injury with dronedarone. In PALLAS, a study of patients with permanent atrial fibrillation, the data and safety monitoring committee stopped the trial early when they noticed an increased risk of cardiovascular events among patients with permanent atrial fibrillation treated with the drug compared with placebo. The CHMP initiated the review of the overall balance of benefit and risk early this year based on reports of severe liver injury with dronedarone. During the review, PALLAS was halted, and the committee was made aware of the increased risk of cardiovascular side effects—cardiovascular death, hospitalization, and stroke—with dronedarone, and based on this included cardiovascular safety in its overall assessment of the drug.
Based on its review, the CHMP was concerned that the "cardiovascular events shown in the population in the PALLAS study could mean an increased risk of cardiovascular side effects for some patients with nonpermanent atrial fibrillation." Despite restricting use, there are limited treatment options for patients with nonpermanent atrial fibrillation, according to the CHMP, so dronedarone might be a useful treatment option in selected patients.
The CHMP therefore was of the opinion that "the benefits of Multaq outweigh its risks in these patients, provided that further changes to the information for prescribers and patients will be introduced to minimize the risk of injury to the liver, lung, and heart."....